Cell Signaling · Skim version

Drugs Against a Part

About 1 min to skim · 3 figures

Read the full lesson → Skim the whole course →

The guiding idea

About five hundred human kinases hold ATP in nearly the same pocket. How do you drug just one?

A targeted drug acts on one named part of a signalling pathway.

  1. A decoy in the receptor: fit without the push

    AI-generated illustration: two copies of a receptor in a membrane. Left, adrenaline sits in the binding site, the inside part of the receptor changes shape, and an arrow leads to 'Signal'. Right, propranolol sits in the same site, the receptor keeps its resting shape, adrenaline floats above unable to enter, and a dashed empty box reads 'No signal'.
    Fitting a receptor and switching it on are separable. An antagonist such as propranolol sits in the receptor's own site without switching it on, and while it is there adrenaline cannot get in. AI-generated illustration
  2. One pocket, five hundred kinases: “Highly Conserved— target for lots of drugs”

  3. When the drug stops working: one residue changed

  4. The target nobody could hit: a bond to the mutation itself

  5. Outside, inside, beside: the sorting, and what the network does next

    AI-generated illustration: five numbered panels in a row, each with a labeled callout and a gold drug on a blue-gray protein. 1, a small drug in a membrane receptor's own binding site. 2, a Y-shaped antibody on the outside face of a membrane receptor. 3, a drug in a kinase's ATP pocket, with ATP shown beside it. 4, a drug beside an enzyme's empty active site. 5, a drug bonded through a short linker to a single mutant residue on Ras.
    Five ways targeted drugs bind: a receptor's ligand site, a receptor's outer surface, a kinase's ATP pocket, a site beside the active site, and covalent attachment to a mutant residue. The categories overlap: sotorasib binds a pocket beside the nucleotide site of K-Ras G12C and also bonds cysteine 12. AI-generated illustration
    AI-generated illustration: two panels. Feedback relieved: a receptor, Ras, Raf, MEK and ERK in a column, with a MEK inhibitor on MEK, a faint dashed arrow from MEK to ERK, ERK's dashed brake line back to the receptor and Ras, and burst marks around the upstream steps. A bypass: an EGF receptor with an inhibitor in it, beside three MET receptors whose arrows drive Ras, Raf, MEK and ERK.
    Wherever a drug lands, the network answers. Blocking MEK relieves ERK's negative feedback, so upstream steps push harder and the pathway can partly switch itself back on; in some lung cancers treated with an EGF receptor inhibitor, extra copies of MET switch the same pathways on again. AI-generated illustration

Read the full lesson → Skim the whole course →